Lupus Erythematosus

Renata M., 31, a paralegal on a demanding discovery-review team, has skin and joint lupus that hasn't responded to hydroxychloroquine or methotrexate. The disagreement is which biologic actually fits her disease pattern, once the two pivotal trials behind each drug are read for what they really tested.

T.O., 42, who runs a bakery's early-morning shift, has cutaneous-predominant lupus that's stayed resistant to treatment. The disagreement is whether anifrolumab, proven in systemic disease, is being reached for here because it fits her, or because it's the newest option in the room.

D.K., 38, a high school chemistry teacher, has recurrent pleuritic chest pain and pericarditis from lupus that keeps recurring despite treatment. The disagreement is which B-cell-depleting drug to reach for when neither one's pivotal trial actually enrolled a patient with her specific problem.

Priya S., 27, a software engineer timing a pregnancy around her company's parental-leave policy, has lupus arthritis that needs a second agent — and eighteen months is not as much runway as it sounds for some of the options on the table.

A.F., 24, a graduate student in her final year, developed new hallucinations and a seizure while on high-dose steroids for lupus. The disagreement is whether her own disease or the drug treating it is the actual cause — and the case is honest that nothing available answers that question cleanly.

M.R., 33, a high school volleyball coach, arrived with worsening abdominal pain, new nailfold infarcts, and a cold, mottled hand. The disagreement is which second agent to commit to for suspected lupus vasculitis, and how much an emergency imaging result should be allowed to change the answer.

J.B., 46, who manages warehouse operations, has been controlled on a hydroxychloroquine dose that turns out to sit over her own weight-based retinopathy ceiling. The disagreement is how to close a twenty-milligram gap without giving up the control that took two failed dose reductions to find.

K.N., 30, a nurse hoping to start a family in a couple of years, needs bone protection against her chronic steroid use. The disagreement is that the safest-looking exit from one option turns out to land a different risk directly inside the pregnancy it was supposed to protect.

S.A., 35, a high school counselor, has triple-positive antiphospholipid antibodies and has never had a clot. The disagreement is whether a negative primary-prevention aspirin trial genuinely applies to a risk profile as high as hers, or whether she was never really represented in it.

L.V., 26, who manages a restaurant, found out this morning she's unexpectedly pregnant while on a drug that can't be continued. The disagreement is how to switch her fast enough to protect the pregnancy without skipping a genetic test that's supposed to come before the replacement drug, not after.

C.J., 24, an on-air meteorologist, was diagnosed with lupus three weeks ago with a severe rash already threatening visible scarring. The disagreement is whether her scarring risk justifies skipping straight to a biologic, ahead of the sequence guidelines usually expect her to go through first.

W.T., 61, a retired postal carrier with severe heart failure and kidney disease, has developed drug-induced lupus from one of his only remaining heart failure options. The disagreement almost missed a second, more dangerous possibility hiding behind the first — hydralazine's own separate, unrelated kidney risk.

N.E., 22, in her final semester of college, was admitted with a platelet count of 6,000 and gum bleeding from lupus. The disagreement over what comes after IVIG very nearly skipped the one test that should happen before any of the remaining options are considered safe to stack.